

Table 2.3
Verified Outcomes (Annualized Percentages) by Race/Ethnicity for Hormone Therapy Participants

Data as of: September 30, 2015; Events through September 30, 2015

Outcomes	Race/Ethnicity					
	American Indian/ Alaskan Native	Asian/Pacific Islander	Black/African American	Hispanic/ Latino	White	Unknown
Number randomized	130	527	2738	1537	22030	385
Mean follow-up (months)	154.7	156.2	161.1	148.6	174.9	161.6
Cardiovascular						
CHD ¹	10 (0.60%)	26 (0.38%)	191 (0.52%)	51 (0.27%)	1847 (0.58%)	29 (0.56%)
CHD death ²	6 (0.36%)	10 (0.15%)	88 (0.24%)	14 (0.07%)	657 (0.20%)	7 (0.14%)
Total MI ³	6 (0.36%)	21 (0.31%)	124 (0.34%)	39 (0.20%)	1400 (0.44%)	25 (0.48%)
Clinical MI	6 (0.36%)	20 (0.29%)	123 (0.33%)	37 (0.19%)	1375 (0.43%)	24 (0.46%)
Angina ⁴	7 (0.69%)	14 (0.34%)	125 (0.57%)	44 (0.37%)	884 (0.49%)	12 (0.40%)
CABG/PTCA	10 (0.60%)	22 (0.32%)	150 (0.41%)	65 (0.34%)	1797 (0.56%)	29 (0.56%)
Carotid artery disease	1 (0.06%)	3 (0.04%)	16 (0.04%)	4 (0.02%)	361 (0.11%)	3 (0.06%)
Congestive heart failure, WHI ⁴	3 (0.30%)	9 (0.22%)	99 (0.45%)	29 (0.24%)	655 (0.36%)	11 (0.37%)
Heart failure, UNC ⁵	7 (0.42%)	18 (0.26%)	161 (0.44%)	38 (0.20%)	1437 (0.45%)	17 (0.33%)
Stroke	10 (0.60%)	18 (0.26%)	181 (0.49%)	35 (0.18%)	1364 (0.42%)	23 (0.44%)
Non-disabling stroke ⁶	5 (0.30%)	9 (0.13%)	103 (0.28%)	22 (0.12%)	724 (0.23%)	10 (0.19%)
Fatal/disabling stroke ⁶	5 (0.30%)	9 (0.13%)	67 (0.18%)	10 (0.05%)	593 (0.18%)	10 (0.19%)
Unknown status from stroke ⁶	0 (0.00%)	0 (0.00%)	11 (0.03%)	3 (0.02%)	47 (0.01%)	3 (0.06%)
PVD	3 (0.18%)	6 (0.09%)	46 (0.13%)	7 (0.04%)	353 (0.11%)	4 (0.08%)
DVT	5 (0.30%)	4 (0.06%)	84 (0.23%)	11 (0.06%)	731 (0.23%)	4 (0.08%)
Pulmonary embolism	4 (0.24%)	2 (0.03%)	77 (0.21%)	7 (0.04%)	560 (0.17%)	9 (0.17%)
DVT/PE	8 (0.48%)	4 (0.06%)	127 (0.35%)	15 (0.08%)	1029 (0.32%)	11 (0.21%)
Coronary disease ⁷	20 (1.19%)	54 (0.79%)	443 (1.21%)	136 (0.71%)	3903 (1.22%)	56 (1.08%)
Aortic aneurysm ⁸	0 (0.00%)	0 (0.00%)	6 (0.05%)	1 (0.02%)	24 (0.03%)	0 (0.00%)
Atrial fibrillation ⁸	0 (0.00%)	2 (0.09%)	17 (0.15%)	11 (0.17%)	731 (0.80%)	10 (0.62%)
Valvular heart disease ⁸	1 (0.19%)	1 (0.05%)	7 (0.06%)	7 (0.11%)	181 (0.20%)	3 (0.19%)
Total cardiovascular disease⁹	34 (2.03%)	77 (1.12%)	707 (1.92%)	184 (0.97%)	5972 (1.86%)	77 (1.49%)
Cancer						
Breast cancer	8 (0.48%)	32 (0.47%)	149 (0.41%)	57 (0.30%)	1464 (0.46%)	18 (0.35%)
Invasive breast cancer	7 (0.42%)	24 (0.35%)	120 (0.33%)	48 (0.25%)	1209 (0.38%)	14 (0.27%)
Non-invasive breast cancer	1 (0.06%)	9 (0.13%)	31 (0.08%)	10 (0.05%)	277 (0.09%)	5 (0.10%)
Ovarian cancer	1 (0.06%)	3 (0.04%)	11 (0.03%)	2 (0.01%)	136 (0.04%)	4 (0.08%)
Endometrial cancer ¹⁰	1 (0.06%)	2 (0.03%)	15 (0.04%)	6 (0.03%)	188 (0.06%)	2 (0.04%)
Colorectal cancer	1 (0.06%)	17 (0.25%)	46 (0.13%)	20 (0.11%)	483 (0.15%)	9 (0.17%)
Other cancer ¹¹	12 (0.72%)	44 (0.64%)	175 (0.48%)	78 (0.41%)	2293 (0.71%)	32 (0.62%)
Total cancer	22 (1.31%)	95 (1.39%)	368 (1.00%)	154 (0.81%)	4262 (1.33%)	61 (1.18%)
Fractures						
Hip fracture	4 (0.24%)	8 (0.12%)	23 (0.06%)	18 (0.09%)	1007 (0.31%)	10 (0.19%)
Deaths						
Cardiovascular deaths	11 (0.66%)	16 (0.23%)	173 (0.47%)	28 (0.15%)	1410 (0.44%)	15 (0.29%)
Cancer deaths	8 (0.48%)	34 (0.50%)	143 (0.39%)	60 (0.32%)	1508 (0.47%)	22 (0.42%)
Other known cause	7 (0.42%)	19 (0.28%)	98 (0.27%)	32 (0.17%)	1328 (0.41%)	16 (0.31%)
Unknown cause	0 (0.00%)	1 (0.01%)	4 (0.01%)	3 (0.02%)	34 (0.01%)	2 (0.04%)
Not yet adjudicated	1 (0.06%)	2 (0.03%)	14 (0.04%)	2 (0.01%)	237 (0.07%)	4 (0.08%)
Total Death	27 (1.61%)	72 (1.05%)	432 (1.18%)	125 (0.66%)	4517 (1.41%)	59 (1.14%)
Death plus post-WHI deaths¹²	34 (1.63%)	119 (1.39%)	673 (1.52%)	241 (0.93%)	6267 (1.73%)	93 (1.49%)

¹ "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2015.

² "CHD death" includes definite and possible CHD death.

³ "Total MI" includes clinical MI and evolving Q-wave MI; Q-wave MI is not collected in the WHI Extension Studies 2005-2015.

⁴ Angina and CHF are not verified outcomes during the WHI Extension Studies 2005-2015. Reported statistics represent experience during the original program.

⁵ Definite or possible decompensated heart failure adjudicated by UNC.

⁶ Non-disabling stroke includes Glasgow scales 1 and 2; fatal/disabling includes Glasgow scales 3-5 and death within 1 month of stroke; and unknown status includes Glasgow scale 6 and status not yet known.

⁷ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina and CHF are not collected in the WHI Extension Studies 2005-2015.

⁸ Aortic aneurysm, atrial fibrillation and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2015.

⁹ Total CVD does not include aortic aneurysm, atrial fibrillation or valvular heart disease.

¹⁰ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

¹¹ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

¹² Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.